Abstract:Background: Yes-associated protein 1 (YAP1) is the main downstream effector of the Hippo signaling pathway, which is involved in tumorigenesis. This study aimed to comprehensively understand the prognostic performances of YAP1 expression and its potential mechanism in pan-cancers by mining databases. Methods: The YAP1 expression was evaluated by the Oncomine database and GEPIA tool. The clinical significance of YAP1 expression was analyzed by the UALCAN, GEPIA, and DriverDBv3 database. Then, the co-expressed genes with YAP1 were screened by the LinkedOmics, and annotated by the Metascape and DAVID database. Additionally, by the MitoMiner 4.0 v tool, the YAP1 co-expressed genes were screened to obtain the YAP1-associated mitochondrial genes that were further enriched by DAVID and analyzed by MCODE for the hub genes. Results: YAP1 was differentially expressed in human cancers. Higher YAP1 expression was significantly associated with poorer overall survival and disease-free survival in adrenocortical carcinoma (ACC), brain Lower Grade Glioma (LGG), and pancreatic adenocarcinoma (PAAD). The LinkedOmics analysis revealed 923 co-expressed genes with YAP1 in adrenocortical carcinoma, LGG and PAAD. The 923 genes mainly participated in mitochondrial functions including mitochondrial gene expression and mitochondrial respiratory chain complex I assembly. Of the 923 genes, 112 mitochondrial genes were identified by MitoMiner 4.0 v and significantly enriched in oxidative phosphorylation. The MCODE analysis identified three hub genes including CHCHD1, IDH3G and NDUFAF5. Conclusion: Our findings showed that the YAP1 overexpression could be a biomarker for poor prognosis in ACC, LGG and PAAD. Specifically, the YAP1 co-expression genes were mainly involved in the regulation of mitochondrial function especially in oxidative phosphorylation. Thus, our findings provided evidence of the carcinogenesis of YAP1 in human cancers and new insights into the mechanisms underlying the role of YAP1 in mitochondrial dysregulation.

The role of YAP1 in liver cancer stem cells: proven and potential mechanisms

Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells.

The Role of YAP Transcription Coactivator in Regulating Stem Cell Self-Renewal and Differentiation.

The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis

Targeting YAP and Hippo Signaling Pathway in Liver Cancer

Yes-associated Protein: A Novel Molecular Target for the Diagnosis, Treatment and Prognosis of Hepatocellular Carcinoma

Roles of Yes-associated Protein and Transcriptional Coactivator with PDZ-binding Motif in Non-Neoplastic Liver Diseases.

The Hippo/YAP1 Pathway Interacts with FGFR1 Signaling to Maintain Stemness in Lung Cancer.

Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice

The role of Hippo/YAP1 in cancer-associated fibroblasts: literature review and future perspectives

Dual Roles of Yes-Associated Protein (yap) in Colorectal Cancer

YAP in pancreatic cancer: oncogenic role and therapeutic strategy

The Dual Functions of YAP-1 to Promote and Inhibit Cell Growth in Human Malignancy.

Role of YAP in Lung Cancer Resistance to Cisplatin.

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.

Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

Mutual Interaction Between Yap and Creb Promotes Tumorigenesis in Liver Cancer